Pioneering Cholesterol Trafficking Solutions

Mandos LLC is a wholly-owned subsidiary of Beren Therapeutics Public Benefit Corporation (P.B.C.), a biotechnology company committed to the development of adrabetadex for individuals living with Niemann-Pick Disease Type C (NPC), a condition characterized by defects in cholesterol trafficking.

Since 2021, Mandos Health has supported the NPC community by providing access to adrabetadex through its Expanded Access Program (EAP). The company will continue working closely with patients, families, researchers, regulators and others on a path to bring forth this potentially transformative therapy for NPC and other cholesterol trafficking diseases.